The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021.
REUTERS/Johanna Geron/File Photo Acquire Licensing RightsCompanies Absci Corp FollowAstraZeneca PLC FollowDec 3 (Reuters) - Anglo-Swedish drugmaker AstraZeneca (AZN.L) has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci (ABSI.O) to design an antibody to fight cancer, the Financial Times reported on Sunday.
The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said.
Absci and AstraZeneca did not immediately respond to a Reuters requests for comment.
Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
Persons:
Johanna Geron, Sean McClain, Absci’s, Shivani Tanna, William Mallard
Organizations:
AstraZeneca, REUTERS, U.S, Financial Times, Thomson
Locations:
Brussels, Belgium, Swedish, Bengaluru